Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
No serious adverse events have been systematically documented in human use to date, though the absence of systematic reporting infrastructure in the research peptide space means that adverse events are almost certainly underreported
The designation acknowledges safety data gaps that preclude traditional drug compounding
The peptides have been extensively studied individually with strong safety data
As of August 2025, we had collected over 27,885 survey respondents who had reported using at least one of Ozempic, Wegovy, compounded semaglutide, Mounjaro, Zepbound or compounded tirzepatide (Extended Data Table 1)
US$ 27.69
US$ 28.59
US$ 27.06
US$ 28.99
US$ 27.21
US$ 29.72
US$ 20.40
US$ 20.08
